中国将从2026年1月1日起通过私人保险覆盖早期阿尔茨海默氏症的Leqembi。 China will cover Leqembi for early Alzheimer’s via private insurance starting Jan 1, 2026.

Leqembi(Lecanemab)是早期阿尔茨海默氏病的治疗,已被列入2026年1月1日生效的中国商业保险创新药品清单。 Leqembi (lecanemab), a treatment for early Alzheimer’s disease, has been added to China’s Commercial Insurance Innovative Drug List, effective January 1, 2026. 中国国家医疗安全署于2025年12月8日宣布, 允许商业保险公司承保药品, 让早期阿尔茨海默氏症患者更容易获得创新治疗。 The inclusion, announced by China’s National Healthcare Security Administration on December 8, 2025, allows commercial insurers to cover the drug, improving access to this innovative therapy for patients with early-stage Alzheimer’s. 药物针对的是作为疾病不断演变中的关键蛋白质的氨基质-贝塔蛋白质,在51个国家获得批准。 The drug targets amyloid-beta protofibrils, a key protein in disease progression, and is approved in 51 countries. 它于2024年6月在中国的私人市场推出,通过静脉注射或亚皮注射提供。 It was launched in China’s private market in June 2024 and is available via intravenous or subcutaneous injection. 中国阿尔茨海默氏病病例不断上升, 超过1700万人在2024年有轻度认知障碍或轻微痴呆。 The move supports broader access to cutting-edge treatments amid rising Alzheimer’s cases in China, where over 17 million people had mild cognitive impairment or mild dementia in 2024.